Pfizer to pay $55M in drug misbranding

  • Associated Press December 12, 2012

WASHINGTON — The Justice Department says Pfizer Inc. will pay $55 million to resolve allegations that Wyeth LLC promoted the drug Protonix for uses that were not approved by the Food and Drug Administration. Pfizer acquired Wyeth in October 2009.

Wyeth obtained FDA approval to promote Protonix only for short-term treatment of erosive esophagitis. The condition is associated with gastro-esophageal reflux disease. Wyeth allegedly promoted Protonix for all forms of GERD from February 2000 to June 2001.

GERD is a condition in which food or liquid leaks backwards from the stomach into the esophagus.


blog comments powered by Disqus

Cyber Monday sales still on top, but losing some luster

Fed moves to bar bailouts of failing firms

Pending homes sales edge up in October

PA Mug Co. owner moves to new studio space in Waynesburg

On the money: Making sure green home upgrades pay off

Dakota city that grew on fracking reaching out for more retail

Super Bowl of shopping unfolds

Coat giveaway better than any Black Friday sale

Orders for U.S. durable goods rise strong 3 percent in October

Applications for U.S. unemployment benefits fall to 260,000